Incyte Corporation (NASDAQ:INCY - Get Free Report) has received an average recommendation of "Hold" from the twenty-five brokerages that are currently covering the stock, MarketBeat.com reports. Fourteen research analysts have rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $133.86.
A number of brokerages recently issued reports on INCY. Canaccord Genuity Group started coverage on Incyte in a report on Thursday, August 20th. They set a "buy" rating and a $152.00 price target on the stock. BMO Capital Markets reiterated a "market perform" rating on shares of Incyte in a report on Tuesday, October 27th. Guggenheim lifted their price objective on Incyte from $136.00 to $150.00 and gave the stock a "buy" rating in a research report on Wednesday, July 29th. UBS Group set a $152.00 target price on Incyte in a research note on Friday, October 30th. Finally, Cantor Fitzgerald restated a "neutral" rating on shares of Incyte in a report on Friday, September 11th.
Read Our Latest Report on Incyte
Incyte Trading Down 1.1%
INCY stock opened at $117.80 on Thursday. The firm's 50-day moving average price is $118.78 and its two-hundred day moving average price is $109.23. Incyte has a 12-month low of $89.25 and a 12-month high of $132.60. The stock has a market capitalization of $24.01 billion, a price-to-earnings ratio of 62.66, a PEG ratio of 4.24 and a beta of 0.78.
Incyte (NASDAQ:INCY - Get Free Report) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share for the quarter, topping analysts' consensus estimates of ($3.93) by $0.33. The company had revenue of $1.56 billion during the quarter, compared to analyst estimates of $1.46 billion. Incyte had a net margin of 6.71% and a return on equity of 7.92%. Incyte's revenue for the quarter was up 14.0% on a year-over-year basis. During the same period in the prior year, the business posted $2.26 earnings per share. Equities analysts predict that Incyte will post 2.29 EPS for the current year.
Key Headlines Impacting Incyte
Here are a few of the latest headlines about INCY:
- Positive Sentiment: The European Commission approved Povofortay (povorcitinib) as the first once-daily oral treatment for adults with moderate-to-severe hidradenitis suppurativa (HS) in Europe. Approval opens a new commercial opportunity, though the reports provide no sales forecast or launch details. Incyte approval announcement
- Positive Sentiment: Piper Sandler maintained its Buy rating on Incyte, signaling continued analyst confidence, although the provided report does not include a revised price target or new rationale. Piper Sandler rating report
- Neutral Sentiment: EVP Lee Heeson sold 10,694 shares worth about $1.29 million, reducing his direct holdings by 28.46%. The trade was made under a pre-arranged Rule 10b5-1 plan, making it a less definitive signal about his outlook for Incyte. Insider sale report
Insider Transactions at Incyte
In other Incyte news, insider Thomas Tray sold 610 shares of the stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $118.96, for a total value of $72,565.60. Following the completion of the transaction, the insider owned 21,126 shares in the company, valued at approximately $2,513,148.96. This represents a 2.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Steven Stein sold 240,193 shares of the business's stock in a transaction on Friday, November 6th. The shares were sold at an average price of $118.39, for a total transaction of $28,436,449.27. Following the sale, the chief marketing officer owned 30,916 shares in the company, valued at approximately $3,660,145.24. This trade represents a 88.60% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 254,139 shares of company stock valued at $30,098,844. Insiders own 16.20% of the company's stock.
Hedge Funds Weigh In On Incyte
A number of hedge funds have recently added to or reduced their stakes in INCY. BlackRock Inc. bought a new position in Incyte in the 2nd quarter valued at approximately $2,044,189,000. Wellington Management Group LLP boosted its stake in Incyte by 9.5% during the 2nd quarter. Wellington Management Group LLP now owns 3,575,521 shares of the biopharmaceutical company's stock valued at $405,321,000 after purchasing an additional 309,385 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Incyte by 10.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,975,544 shares of the biopharmaceutical company's stock worth $185,873,000 after purchasing an additional 187,354 shares in the last quarter. First Trust Advisors LP increased its holdings in shares of Incyte by 15.2% in the 3rd quarter. First Trust Advisors LP now owns 1,829,078 shares of the biopharmaceutical company's stock worth $221,959,000 after purchasing an additional 241,082 shares in the last quarter. Finally, Pacer Advisors Inc. raised its stake in shares of Incyte by 2.2% in the first quarter. Pacer Advisors Inc. now owns 1,741,061 shares of the biopharmaceutical company's stock worth $163,869,000 after purchasing an additional 37,790 shares during the last quarter. 96.97% of the stock is currently owned by hedge funds and other institutional investors.
About Incyte
(
Get Free Report)
Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Incyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Incyte wasn't on the list.
While Incyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.